

Phenotypic characterization of patients with deletions in the 3'-flanking *SHOX* region

Sarina G. Kant¹, Sander J. Broekman², Caroline C. de Wit², Marloes Bos¹, Sitha A. Scheltinga², Egbert Bakker², Wilma Oostdijk³, Hetty J. van der Kamp³, Erik W. van Zwet⁴, Annemieke H. van der Hout⁵, Jan M. Wit³ and Monique Losekoot²

¹ CHCG-Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands

² CHCG-Laboratory for Diagnostic Genome Analysis, Leiden University Medical Center, Leiden, The Netherlands

³ Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands

⁴ Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands

⁵ Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

ABSTRACT

Context. Leri–Weill dyschondrosteosis is a clinically variable skeletal dysplasia, caused by *SHOX* deletion or mutations, or a deletion of enhancer sequences in the 3'-flanking region. Recently, a 47.5 kb recurrent PAR1 deletion downstream of *SHOX* was reported, but its frequency and clinical importance are still unknown.

Objective. This study aims to compare the clinical features of different sizes of deletions in the 3'-flanking *SHOX* region in order to determine the relevance of the regulatory sequences in this region.

Design. We collected DNA from 28 families with deletions in the 3'-PAR1 region. Clinical data were available from 23 index patients and 21 relatives.

Results. In 9 families (20 individuals) a large deletion (~200–900 kb) was found and in 19 families (35 individuals) a small deletion was demonstrated, equal to the recently described 47.5 kb PAR1 deletion. Median height SDS, sitting height/height ratio SDS and the presence of Madelung deformity in patients with the 47.5 kb deletion were not significantly different from patients with larger deletions. The index patients had a median height SDS which was slightly lower than in their affected family members ($p = 0.08$). No significant differences were observed between male and female patients.

Conclusions. The phenotype of patients with deletions in the 3'-PAR1 region is remarkably variable. Height, sitting height/height ratio and the presence of Madelung deformity were not significantly different between patients with the 47.5 kb recurrent PAR1 deletion and those with larger deletions, suggesting that this enhancer plays an important role in *SHOX* expression.

Submitted 21 November 2012

Accepted 18 January 2013

Published 19 February 2013

Corresponding author

Sarina G. Kant, s.g.kant@lumc.nl

Academic editor

David Meyre

Additional Information and
Declarations can be found on
page 8

DOI 10.7717/peerj.35

© Copyright
2013 Kant et al.

Distributed under
Creative Commons CC-BY 3.0

OPEN ACCESS

Subjects Genetics, Medical Genetics, Pediatrics, Statistics

Keywords Downstream deletion, Phenotype, *SHOX*, Short stature, Disproportion, Madelung

INTRODUCTION

Leri–Weill dyschondrosteosis (LWD) is caused by haploinsufficiency of *SHOX* in 60–70% of cases (intragenic deletions, duplications or mutations), and in 15–31% of patients without an intragenic mutation or deletion a putative enhancer sequence in the 3'-flanking region has been demonstrated (*Benito-Sanz et al., 2005; Chen et al., 2009*). *SHOX* is located on the short arm of the X-chromosome in the pseudoautosomal (PAR) 1 region, thereby escaping X-inactivation, leading to a pseudoautosomal pattern of inheritance for LWD (*Belin et al., 1998; Shears et al., 1998*). So far, 7 enhancer sequences, 3 upstream and 4 downstream of *SHOX*, have been described (*Fukami et al., 2006; Sabherwal et al., 2007; Durand et al., 2010; Kenyon et al., 2011; Benito-Sanz et al., 2012a; Benito-Sanz et al., 2012b*). Deletion of one or more of the downstream enhancer sequences results in *SHOX* haploinsufficiency and LWD. *Benito-Sanz et al. (2005)* as well as *Chen et al. (2009)* described a cohort of patients with different deletions in the downstream enhancer region, where various deletion sizes all resulted in LWD or idiopathic short stature. A deletion in the enhancer region upstream of *SHOX* has only recently been reported in one female patient and her father with idiopathic short stature (*Benito-Sanz et al., 2012a*), where two of the three upstream enhancer sequences were deleted.

LWD caused by a heterozygous mutation or deletion of *SHOX* is characterized by short stature, mesomelia, and Madelung deformity. Penetrance of the phenotype appears to be incomplete within families (*Rappold et al., 2007; Binder, 2011*) and Madelung deformity and short stature tend to be more common and severe in females than in males (*Binder, 2011*). Mean height of index cases has been reported as -2.2 SDS (*Binder, 2011; Rosilio et al., 2012*) and height of affected mothers and fathers as -2.1 SDS and -1.6 SDS, respectively (*Rosilio et al., 2012*).

There is limited information about the phenotype of patients with a deletion in the enhancer region downstream of *SHOX*. However, from the available reports the phenotypic characteristics do not seem to differ much from those of patients with *SHOX* deletions or mutations (*Benito-Sanz et al., 2005; Salmon-Musial et al., 2011; Rosilio et al., 2012*).

Recently, a relatively small deletion of PAR1 was found by *Caliebe et al. (2012)* in a father and son, of whom the son had short stature (-2.0 SDS), while the father did not (-0.44 SDS). Comparable deletions were already demonstrated by *Chen et al. (2009)*, but their exact size was not determined in detail. Subsequently this deletion was described in 30 unrelated families with LWD or ISS by *Benito-Sanz et al. (2012b)* equivalent to 15.3% of probands with LWD and 1.9% of probands with idiopathic short stature, uncovering a novel downstream enhancer. The clinical phenotype of these patients showed a wide variability with height SDS ranging from -0.14 to -4.68 .

We aimed at investigating the frequency of the various deletions in the 3'-flanking *SHOX* region and the possible phenotypic differences between patients with different sizes of deletions in this region.

METHODS

Clinical characteristics

In 49 DNA samples sent to the Laboratory for Diagnostic Genome Analysis of the Department of Clinical Genetics (Leiden University Medical Center, Leiden) and in six of the DNA samples sent to the Section Genome Diagnostics of the Department of Genetics (University Medical Center Groningen, Groningen), for the determination of *SHOX* defects between 2005 and 2011, we found a deletion in the downstream enhancer region of *SHOX* in 29 probands, and 26 of their relatives (total of 28 families). In the same period in the Laboratory for Diagnostic Genome Analysis of the Department of Clinical Genetics (Leiden University Medical Center, Leiden) we detected 43 deletions of the complete gene, 22 mutations (missense, nonsense, splice site or frameshift) and 5 duplications of *SHOX* in a total of 1045 patients.

With consent of the Medical Ethical Committee of the LUMC, clinical data were collected and anonymized for 44 of the 55 patients (23 index patients and 21 affected relatives from 23 families). Two of the remaining 11 patients were excluded from the analysis of clinical features, because they suffered from an additional disorder, which would probably influence their growth (a skeletal dysplasia of unknown type (inconsistent with LWD), and a deletion 22q11, respectively). For 9 patients no additional clinical data could be obtained.

Demographic and clinical data collected were sex, age, height standard deviation score (SDS), sitting height to height ratio SDS and presence of Madelung deformity. Height SDS and sitting height/height SDS were calculated based on Dutch nation-wide references ([Fredriks et al., 2005](#)). We chose not to collect all data needed to calculate the Rappold score ([Rappold et al., 2007](#)), because of the limitations of this scoring system in clinical practice: arm span, and length and bowing of the forearm are seldom measured by clinicians, appearance of muscular build is not very often spontaneously mentioned in clinical records, and the use of body mass index gives a higher score for obese patients. Instead, we chose to collect data about the classical clinical triad of Leri–Weill dyschondrosteosis: height, sitting height to height ratio (SH/H) and presence of Madelung deformity.

Molecular analysis

DNA isolation from peripheral blood and sequence analysis of the *SHOX* coding region including intron–exon boundaries was performed using standard procedures (primer sequences available upon request). Deletions and duplications were detected using the MRC-Holland MLPA kit (Salsa P018-D1) according to the manufacturer's instructions.

Statistical analysis

The *t*-test and Fisher exact test were used to test for an association of genotype (deletion including PAR1 probes L05099-L05101 or larger deletions) with height SDS, SH/H SDS, and the presence of a Madelung deformity. Differences between index patients and their relatives were determined, as well as the influence of the gender of the patient.




Figure 1 Schematic representation of the SHOX locus and the surrounding enhancer regions. Schematic representation of the SHOX locus and location of the 3'-flanking PAR1 probes of the P018-D1 MLPA kit (MRC Holland). Extent of the deletions (blue bars) and the number of families (n) is indicated with the number of affected individuals between brackets. The SHOX gene is indicated with a purple box. The PAR1 probes are indicated with an * and the four downstream enhancers (ECN4, ECN5, ECR1/CNE7 and CNE9) are indicated with green or red (the enhancer within the 47.5 deletion) triangles. The deletion described by Sabherwal includes PAR1 probe L05096-L05101.

RESULTS

Of the 28 families, 19 had the recurrent 47543 bp (47.5 kb) deletion encompassing PAR1 probes L05099-L05101 described by *Benito-Sanz et al. (2012b)*, containing a SHOX enhancer sequence (ECR1/CNE7). The deletion was found in 19 index cases and 16 of their relatives. Nine families (10 index patients and 10 relatives) had a larger deletion varying from a deletion that includes PAR1 probes L05096-L05104 to a deletion including PAR1 probes L05098-L05103 (*Fig. 1*).

In the 44 individuals (23 families) of whom clinical information was available, mean height SDS was -1.9 (range -4.0 to 1.2) and SH/H SDS 1.5 (range -1.6 to 3.0). Madelung deformity was present in 19 of 33 patients. Mean height SDS and SH/H SDS in patients with the 47.5 kb deletions ($n = 25$) compared to patients with larger deletions ($n = 19$) are shown in *Fig. 2*. Patients with the 47.5 kb deletion were on average 0.5 SD shorter than patients with larger deletions, but the difference did not reach statistical significance ($p = 0.20$). A comparison of the same clinical characteristics between the index patients and their affected relatives, and between male and female patients, is also shown in *Fig. 2*. No significant differences were observed in the different subgroups of patients, as illustrated in *Figs. 2* and *3*. Presence or absence of a Madelung deformity in the subgroups of patients mentioned above is summarized in *Table 1*. No significant differences were observed in any of the subgroups.

DISCUSSION

We show that the recently reported recurrent 47543 bp (47.5 kb) deletion (*Benito-Sanz et al., 2012b*) could also be demonstrated in 19 out of 28 Dutch families (68%) with a downstream deletion and has a similar clinical phenotype as larger deletions in the




Figure 2 Height (SDS) range in different subgroups of patients. Height (SDS) range in different subgroups of patients with a deletion in the downstream enhancer region of *SHOX*. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of *SHOX*; other del = larger deletion in the downstream enhancer of *SHOX*; * = mean value; *n* = number of tested individuals; *p* = *p*-value measured by *t*-test.

downstream region of *SHOX*. Height SDS, SH/H SDS and the presence of Madelung deformity all showed a large variation, regardless of deletion size, gender of the patient or whether the patient was an index patient or relative.

We have now shown that these deletions comprise an important part of our patient cohort. The lack of previous reports on this deletion could be due to doubt about the pathogenicity of the deletion, because it is not overlapping the formerly described critical region in the enhancer region (Benito-Sanz et al., 2005). However, recently the same research group convincingly reported this deletion to include a previously uncharacterized *SHOX* enhancer (ECR1/CNE7), proving the deletion to be pathogenic (Benito-Sanz et al., 2012b).

The average height SDS in our index cases (−2.2 SDS) is similar to mean height SDS in cohorts of patients with *SHOX* deletions and mutations (Binder, 2011). In the first report on patients with a deletion in the enhancer region Benito-Sanz et al. (2005) demonstrated 12 families with short stature and/or Madelung deformity with variable severity, with a height SDS ranging from −4.6 SD to 0.85 SD. Rosilio et al. (2012) recently reported a mean height in their patients with a deletion encompassing *SHOX* of −2.3 SDS, while in the same study a mean height of −2.2 SDS was seen in patients with any deletion in the downstream region. In a smaller sample of patients with a deletion downstream of *SHOX* in the study of Salmon-Musial et al. (2011) a mean height SDS of −1.4 SDS was demonstrated. The results of these reports are in accordance with our observations, although




Figure 3 Sitting height to height ratio (SDS) range in different subgroups of patients. Sitting height to height ratio (SDS) range in different subgroups of patients with a deletion in the downstream enhancer region of SHOX. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del = larger deletion in the downstream enhancer of SHOX; * = mean value; n = number of tested individuals; p = p -value measured by t -test.

Table 1 Madelung deformity in different subgroups of patients with a deletion in the downstream enhancer region of SHOX. Three comparisons are made in subgroups of patients. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del = larger deletion in the downstream enhancer of SHOX.

	Madelung present	Madelung absent	p -value (Fisher exact test)
Patients with del 47.5 kb ($n = 17$)	11	6	0.49
Patients with other del ($n = 16$)	8	8	
Index patients ($n = 19$)	10	9	0.72
Relatives ($n = 14$)	9	5	
Male patients ($n = 12$)	7	5	0.72
Female patients ($n = 21$)	14	7	

in the two last mentioned reports it is suggested that the phenotype in patients with a deletion in the downstream enhancer region seems to be milder than in patients with a SHOX mutation or deletion. The six patients described by [Salmon-Musial et al. \(2011\)](#) with anomalies downstream of SHOX had a less severe short stature (height SDS -1.4) than those with other gene anomalies (height SDS -2.5 ; $n = 16$). Due to the small size of their sample they were not able to draw firm conclusions. [Rosilio et al. \(2012\)](#) reported a higher percentage of idiopathic short stature (instead of LWD) in patients with a deletion in

the downstream enhancer region interval compared to patients with a *SHOX* mutation or deletion, suggesting a milder phenotype in patients with a downstream deletion. However, classification of patient groups in this study shows some shortcomings, as also acknowledged by the authors, and comparisons must be taken with caution. Furthermore in contrast to the findings of [Rosilio et al. \(2012\)](#); [Chen et al. \(2009\)](#) reported a higher percentage of downstream deletions in LWD patients compared to patients with idiopathic short stature. Therefore, genotype–phenotype correlations do not seem obvious.

Comparing all index patients with their relatives shows that mean height SDS is slightly higher in relatives, although not significantly different ($p = 0.08$), probably due to referral bias. Differences between male and female patients were not observed in our study, contrary to what is known about patients with *SHOX* deletions or mutations where females tend to present with a more severe phenotype than males ([Binder, 2011](#)). However, further confirmation is needed on a larger patient cohort.

The large variability of the phenotype confirms the findings in previous reports on patients with a deletion in the enhancer region 3' of *SHOX* ([Benito-Sanz et al., 2005](#); [Chen et al., 2009](#); [Kant et al., 2011](#); [Salmon-Musial et al., 2011](#); [Rosilio et al., 2012](#)). Not all index patients had short stature, which was also noticed in the study by [Salmon-Musial et al. \(2011\)](#), and has been observed in previous studies ([Binder et al., 2004](#); [Rappold et al., 2007](#)). Looking in detail at this group of eight patients with a height at last examination above -2 SDS, reason for a diagnostic *SHOX* analysis was the presence of Madelung deformity in five of them, and disproportion in combination with familial disproportionate short stature in one patient. Another patient had a recent height measurement of -1.4 SDS, but former height measurements were always around -2 SD, while several family members had disproportionate short stature. The last patient had a height in the normal range, but below her target height range. So, short stature is not always the leading clinical sign to request *SHOX* analysis, and referring clinicians do take into account other clinical characteristics of the patient and their relatives. The variability of the clinical phenotype is not limited to deletions of the enhancer region. Also for LWD caused by *SHOX* mutations or deletions, the phenotype has been described as highly variable ([Binder, 2011](#)). Thus, penetrance of the phenotype appears to be incomplete, even within families.

In conclusion, the phenotype in patients with a deletion in the downstream enhancer region of *SHOX* seems comparable to that of patients with a *SHOX* mutation or deletion, and the variability of the phenotype in the whole group of patients with a deletion in the enhancer region is remarkable. The recurrent 47.5 kb deletion downstream of *SHOX* leads to a phenotype comparable to that of larger deletions in the same region. Our data support that the 47.5 kb deletion is a pathogenic deletion, and therefore it seems plausible that an important enhancer region is located within the deletion interval.

ACKNOWLEDGEMENTS

The authors thank all referring clinicians for providing clinical information about their patients, and V Janmaat for his contribution to the data collection.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

No grants or fellowships funded the research or the writing of this article.

Competing Interests

JM Wit is an Academic Editor for PeerJ.

Author Contributions

- Sarina G. Kant conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper.
- Sander J. Broekman, Caroline C. de Wit, Sitha A. Scheltinga, Wilma Oostdijk and Hetty J. van der Kamp performed the experiments.
- Marloes Bos performed the experiments, analyzed the data.
- Egbert Bakker and Annemieke H. van der Hout analyzed the data.
- Erik W. van Zwet conceived and designed the experiments, analyzed the data.
- Jan M. Wit and Monique Losekoot conceived and designed the experiments, analyzed the data, wrote the paper.

REFERENCES

- Belin V, Cusin V, Viot G, Girlich D, Toutain A, Moncla A, Vekemans M, Le Merrer M, Munnich A, Cormier-Daire V. 1998.** SHOX mutations in dyschondrosteosis (Leri–Weill syndrome). *Nature Genetics* **19**:67–69 DOI [10.1038/ng0198-67](https://doi.org/10.1038/ng0198-67).
- Benito-Sanz S, Thomas NS, Huber C, Gorbenko del Blanco D, Aza-Carmona M, Crolla JA, Maloney V, Rappold G, Argente J, Campos-Barros A, Cormier-Daire V, Heath KE. 2005.** A novel class of Pseudoautosomal region 1 deletions downstream of *SHOX* is associated with Leri–Weill dyschondrosteosis. *American Journal of Human Genetics* **77**:533–544 DOI [10.1086/449313](https://doi.org/10.1086/449313).
- Benito-Sanz S, Aza-Carmona M, Rodríguez-Estevéz A, Rica-Etxebarria I, Gracia R, Campos-Barros A, Heath KE. 2012a.** Identification of the first PAR1 deletion encompassing upstream *SHOX* enhancers in a family with idiopathic short stature. *European Journal of Human Genetics* **20**:125–127 DOI [10.1038/ejhg.2011.210](https://doi.org/10.1038/ejhg.2011.210).
- Benito-Sanz S, Royo JL, Barroso E, Paumard-Hernandez B, Barreda-Bonis AC, Liu P, Gracia R, Lupski JR, Campos-Barros A, Gomez-Skarmeta JL, Heath KE. 2012b.** Identification of the first recurrent PAR1 deletion in Leri–Weill dyschondrosteosis and idiopathic short stature reveals the presence of a novel *SHOX* enhancer. *Journal of Medical Genetics* **49**:442–450 DOI [10.1136/jmedgenet-2011-100678](https://doi.org/10.1136/jmedgenet-2011-100678).
- Binder G, Renz A, Martinez A, Keselman A, Hesse V, Riedl SW, Häusler G, Fricke-Otto S, Frisch H, Heinrich JJ, Ranke MB. 2004.** SHOX haploinsufficiency and Leri–Weill dyschondrosteosis: prevalence and growth failure in relation to mutation, sex, and degree of wrist deformity. *Journal of Clinical Endocrinology and Metabolism* **89**:4403–4408 DOI [10.1210/jc.2004-0591](https://doi.org/10.1210/jc.2004-0591).

- Binder G. 2011.** Short stature due to *SHOX* deficiency: genotype, phenotype, and therapy. *Hormone Research in Paediatrics* 75:81–89 DOI [10.1159/000324105](https://doi.org/10.1159/000324105).
- Caliebe J, Broekman S, Boogaard M, Bosch CA, Ruivenkamp CA, Oostdijk W, Kant SG, Binder G, Ranke MB, Wit JM, Losekoot M. 2012.** IGF1, IGF1R and *SHOX* mutation analysis in short children born small for gestational age and short children with normal birth size (idiopathic short stature). *Hormone Research in Paediatrics* 77:250–260 DOI [10.1159/000338341](https://doi.org/10.1159/000338341).
- Chen J, Wildhardt G, Zhong Z, Röth R, Weiss B, Steinberger D, Decker J, Blum WF, Rappold G. 2009.** Enhancer deletions of the *SHOX* gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain. *Journal of Medical Genetics* 46:834–839 DOI [10.1136/jmg.2009.067785](https://doi.org/10.1136/jmg.2009.067785).
- Durand C, Bangs F, Signolet J, Decker E, Tickle C, Rappold G. 2010.** Enhancer elements upstream of the *SHOX* gene are active in the developing limb. *European Journal of Human Genetics* 18:527–532 DOI [10.1038/ejhg.2009.216](https://doi.org/10.1038/ejhg.2009.216).
- Fredriks AM, van Buuren S, van Heel WJ, Dijkman-Neerincx RH, Verloove-Vanhorick SP, Wit JM. 2005.** Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders. *Archives of Disease in Childhood* 90:807–812 DOI [10.1136/adc.2004.050799](https://doi.org/10.1136/adc.2004.050799).
- Fukami M, Kato F, Tajima T, Yokoya S, Ogata T. 2006.** Transactivation function of an approximately 800-bp evolutionarily conserved sequence at the *SHOX* 3' region: implication for the downstream enhancer. *American Journal of Human Genetics* 78:167–170 DOI [10.1086/499254](https://doi.org/10.1086/499254).
- Kant SG, van der Kamp HJ, Kriek M, Bakker E, Bakker B, Hoffer MJ, van Bunderen P, Losekoot M, Maas SM, Wit JM, Rappold G, Breuning MH. 2011.** The jumping *SHOX* gene–crossover in the pseudoautosomal region resulting in unusual inheritance of Léri–Weill dyschondrosteosis. *Journal of Clinical Endocrinology and Metabolism* 96:E356–359 DOI [10.1210/jc.2010-1505](https://doi.org/10.1210/jc.2010-1505).
- Kenyon EJ, McEwen GK, Callaway H, Elgar G. 2011.** Functional analysis of conserved non-coding regions around the short stature hox gene (*shox*) in whole zebrafish embryos. *PLoS ONE* 6:e21498 DOI [10.1371/journal.pone.0021498](https://doi.org/10.1371/journal.pone.0021498).
- Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL, Niesler B. 2007.** Genotypes and phenotypes in children with short stature: clinical indicators of *SHOX* haploinsufficiency. *Journal of Medical Genetics* 44:306–313 DOI [10.1136/jmg.2006.046581](https://doi.org/10.1136/jmg.2006.046581).
- Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. 2012.** Genotypes and phenotypes of children with *SHOX* deficiency in France. *Journal of Clinical Endocrinology and Metabolism* 97:E1257–1265 DOI [10.1210/jc.2011-3460](https://doi.org/10.1210/jc.2011-3460).
- Sabherwal N, Bangs F, Röth R, Weiss B, Jantz K, Tiecke E, Hinkel GK, Spaich C, Hauffa BP, van der Kamp H, Kapeller J, Tickle C, Rappold G. 2007.** Long-range conserved non-coding *SHOX* sequences regulate expression in developing chicken limb and are associated with short stature phenotypes in human patients. *Human Molecular Genetics* 16:210–222 DOI [10.1093/hmg/ddl470](https://doi.org/10.1093/hmg/ddl470).
- Salmon-Musial AS, Rosilio M, David M, Huber C, Pichot E, Cormier-Daire V, Nicolino M. 2011.** Clinical and radiological characteristics of 22 children with *SHOX* anomalies and familial short stature suggestive of Léri–Weill dyschondrosteosis. *Hormone Research in Paediatrics* 76:178–185 DOI [10.1159/000329359](https://doi.org/10.1159/000329359).
- Shears DJ, Vassal HJ, Goodman FR, Palmer RW, Reardon W, Superti-Furga A, Scambler PJ, Winter RM. 1998.** Mutation and deletion of the pseudoautosomal gene *SHOX* cause Léri–Weill dyschondrosteosis. *Nature Genetics* 19:70–73 DOI [10.1038/ng0198-70](https://doi.org/10.1038/ng0198-70).